Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi SNY for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what makes REGN stock a compelling buy.

SNY earnings call for the period ending December 31, 2024.

Amid the blockbuster gains, some stocks have gone the opposite way, tanking to levels not seen ... The company’s other growth driver, Dupixent, is also doing well, helping shrug off sales ...

Amid the blockbuster gains, some stocks have gone the opposite way, tanking to levels not seen ... The company’s other growth driver, Dupixent, is also doing well, helping shrug off sales ...